Results 61 to 70 of about 1,464,846 (295)

The Mechanisms of PCSK9 Inhibitor Reducing Lipoprotein(a)

open access: yesShengwu huaxue yu shengwu wuli jinzhan
Lipoprotein(a) (Lp(a)) is a complex circulating lipoprotein, and increasing evidence has demonstrated its role as a risk factor for atherosclerotic cardiovascular disease and as a possible therapeutic target.
XUE Yu, LIU Hai-Wei, LI Yang
doaj   +1 more source

Leukocyte low density lipoprotein receptor (LDL-R) does not contribute to LDL clearance in vivo: bone marrow transplantation studies in the mouse

open access: yesJournal of Lipid Research, 1997
The targeted disruption of the low density lipoprotein (LDL) receptor gene in mice results in accumulation of plasma LDL cholesterol and in predisposition to diet-induced aortic atherosclerosis.
S Fazio   +5 more
doaj   +1 more source

Copper‐Doped Prussian Blue Nanozymes With Hyaluronic Acid‐Mediated Targeting Alleviate Oxidative Stress and Regulate Cholesterol Handling for Atherosclerosis Therapy

open access: yesAdvanced Science, EarlyView.
CuPB@HA is a CD44‐associated, plaque‐targeted nanozyme that alleviates oxidative stress, inflammation, and lipid accumulation in macrophages. By reducing CD36‐dependent lipid uptake and promoting ABCA1/ABCG1‐mediated cholesterol handling, it improves macrophage function, preferentially accumulates in atherosclerotic lesions, reduces plaque burden, and ...
Jianliang Ou   +14 more
wiley   +1 more source

Calcium induces a conformational change in the ligand binding domain of the low density lipoprotein receptor

open access: yesJournal of Lipid Research, 1998
We previously have shown that LDL-R354, a truncated low density lipoprotein (LDL) receptor, is a calcium binding protein. LDL-R354 is composed of the ligand binding domain and repeat A of the EGF precursor homology domain of the full-length human LDL ...
Kimberly A. Dirlam-Schatz, Alan D. Attie
doaj   +1 more source

Plaque‐Hepatic Targeting Nanotherapy Disrupts the PCSK9‐LOX‐1 Axis to Suppress oxLDL in Atherosclerosis

open access: yesAdvanced Science, EarlyView.
Self‑amplifying PCSK9–LOX‑1 feedback axis drives atherosclerotic progression by promoting oxLDL generation and endothelial uptake. A dual‑targeting nanoplatform (siPCSK9@PEAL NPs‑aL) is constructed to simultaneously silence hepatic PCSK9 for lipid lowering and block plaque LOX‑1 for anti‑inflammation.
Yi Duan   +7 more
wiley   +1 more source

Expression of low density lipoprotein receptor in cultured human granulosa cells: regulation by human chorionic gonadotropin, cyclic AMP, and sterol.

open access: yesJournal of Lipid Research, 1990
Steroidogenic cells utilize lipoprotein-delivered cholesterol as a primary substrate for hormone synthesis. We studied low density lipoprotein (LDL) receptors in cultured human granulosa cells to determine what factors regulate receptor expression ...
T G Golos, A M August, J F Strauss, 3rd
doaj   +1 more source

S-nitrosylation of ARH is required for LDL uptake by the LDL receptor [PDF]

open access: yesJournal of Lipid Research, 2013
The LDL receptor (LDLR) relies upon endocytic adaptor proteins for internalization of lipoproteins. The results of this study show that the LDLR adaptor autosomal recessive hypercholesterolemia protein (ARH) requires nitric oxide to support LDL uptake.
Zhenze Zhao   +5 more
openaire   +3 more sources

Investigação dos efeitos da cafeína sobre as alterações comportamentais e neuroquímicas apresentadas por camundongos nocautes para o receptor de lipoproteínas de baixa densidade (LDL) [PDF]

open access: yes, 2015
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências Biológicas, Programa de Pós-Graduação em Neurociências, Florianópolis, 2015.A cafeína é uma substância que pode alterar o funcionamento do sistema nervoso central e ...
Szczepanik, Jozimar Carlos
core  

Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins [PDF]

open access: yes, 2014
Statins effectively lower LDL cholesterol levels in large studies and the observed interindividual response variability may be partially explained by genetic variation.
Herrington, D.M.   +627 more
core   +2 more sources

SPARC Drives Podocyte Mitochondrial Damage and Ferroptosis in Diabetic Kidney Disease Following Klotho Deficiency

open access: yesAdvanced Science, EarlyView.
Klotho deficiency promotes podocyte mitochondrial dysfunction and ferroptosis through activation of the PKCα/CUX1/SPARC/TGFβ‐RII axis. SPARC emerges as a key mediator linking Klotho loss to podocyte injury in DKD and other kidney injury models, suggesting broader implications for CKD progression.
Qing Yang   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy